Treating Acute Leukemia During the COVID-19 Pandemic in an Environment With Limited Resources: A Multicenter Experience in Four Latin American Countries Overall CNS relapse rate in the study ...
LEGEND: A randomised phase II study comparing lenalidomide plus rituximab, gemcitabine, and methylprednisolone (R-GEM-L) to rituximab, gemcitabine, methylprednisolone, and cisplatin (R-GEM-P) in ...
Infinity Pharmaceuticals, Inc. (INFI) today announced updated data from a Phase 1 study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with ...
CAMBRIDGE, Mass., Oct. 14, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) announced that results from its Phase 2 study of IPI-504, a novel IV-administered Hsp90 chaperone ...
(HealthDay)—The Burkitt lymphoma (BL) International Prognostic Index (BL-IPI) provides robust discrimination of survival and can be used for prognostication, according to a study published online Jan.
Central nervous system (CNS) relapse occurs in roughly one in 20 patients with diffuse large B-cell lymphoma (DLBCL), but in some disease subtypes that risk increases substantially. "In certain ...
A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse ...
Julio Chavez, MD, MS, of Moffitt Cancer Center, spoke with The American Journal of Managed Care® (AJMC®) about how new approvals will alter decision making in the treatment of diffuse large B-cell ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Hoster: It was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results